GlassScriptPhysician profile
John N Campbell
NPI 1417901232
$8,459.92
in general payments reported to CMS, 2019-2025
51 companies · $1,020 in 2025
The $1,020 reported for 2025 was more than what 89% of Addiction Medicine (Internal Medicine) providers received nationally (typical 2025 total: $124).
See the full distribution for Addiction Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,372 · 2020: $1,664 · 2021: $1,489 · 2022: $983 · 2023: $939 · 2024: $992 · 2025: $1,020.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,951.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,950.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $980.62 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $947.61 | 2019-2025 | |
| Novo Nordisk INC | $681.98 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $652.16 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Vanda Pharmaceuticals INC. | $498.13 | 2019-2021 | |
| Glaxosmithkline, LLC. | $349.68 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $270.91 | 2019-2023 | Veozah |
| Indivior INC. | $262.13 | 2020-2025 | Sublocade |
| Orexo US, INC. | $260.72 | 2019-2024 | Zubsolv |
| Alkermes, INC. | $238.62 | 2020-2025 | Vivitrol, Vivitrol |
| Takeda Pharmaceuticals U.S.A., INC. | $220.48 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $214.98 | 2019-2025 | Rexulti, Abilify Asimtufii, Nuedexta |
| Allergan, INC. | $201.20 | 2020 | |
| Harmony Biosciences LLC | $199.11 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $190.31 | 2019-2025 | Spravato |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.